Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue 6, 2006, Pages 429-435

  Cassinello, Javier ^a   Álvarez, Jose Valero ^b   García López, María José ^c   Pujol, Eduardo ^d   Colmenarejo, Antonio ^e   Segovia, Fernando ^f   Marcos, Fernando ^g   Filipovich, Elena ^h   Arcediano, Alberto ^a   García Castro, Inés ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b Hospital General de Zamora   (Spain)

^c Hospital Alarcos   (Spain)

^d HOSPITAL SANTA BÁRBARA   (Spain)

^e HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^f Hospital Nuestra Señora del Valle   (Spain)

^g HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^h HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

Author keywords

Chemotherapy; Hematologic toxicity; Neutropenia; Thrombocytopenia

Indexed keywords

CAPECITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 33646125402     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.014     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56:106-130.
2. Engstrom PF, Benson AB III, Chen YJ, et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3:468-491.
3. Engstrom PF, Benson AB III, Chen YJ, et al. Rectal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3:492-508.
4. de Gramont A. Rapid evolution in colorectal cancer: therapy now and over the next five years. Oncologist 2005; 10(suppl 2):4-8.
5. de Gramont A, Tournigand C, Louvet C, et al. First-line therapy for advanced colorectal cancer. Curr Oncol Rep 2005; 7:167-172.
6. Saad ED, Hoff PM. Chemotherapy of metastatic colorectal cancer. Curr Treat Options Gastroenterol 2005; 8:239-247.
7. Louvet C, de Gramont A. Colorectal cancer: integrating oxaliplatin. Curr Treat Options Oncol 2003; 4:405-411.
8. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361:2235-2242.
9. Van Cutsem E, Verslype C, Tejpar S. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005; 32:43-51.
10. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10:701-709.
11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
12. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
15. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-2091.
16. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group trial 0108. Cancer 2005; 104:282-289.
17. Twelves C. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Williston Park) 2002; 16(12 suppl 14):23-26.
18. Twelves CJ, Butts CA, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5:101-107.
19. Delord JP, Pierga JY, Dieras V, et al. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 2005; 92:820-826.
20. Sastre J, Massuti B, Tabernero JM, et al. Preliminary results of a randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). J Clin Oncol 2005; 23(16 suppl)252s (Abstract #3524).
21. Maindrault-Goebel F, Tournigand C, Andre T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15:1210-1214.
22. Tourningand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 of FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer- a GERCOR study. J Clin Oncol 2006; 24:394-400.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
24. Hochster HS, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC: TREE 1 & 2 studies. J Clin Oncol 2005; 23(16 suppl)249s (Abstract #3515).